



ViraCor Laboratories and IBT Laboratories Merge to Create Unique Specialty Diagnostics Company

Lee's Summit, MO and Lenexa, KS (July 1, 2009) – ViraCor Laboratories, the leader in molecular diagnostic testing for infectious diseases, and IBT Laboratories, a preeminent clinical-diagnostics and biomedical-research laboratory specializing in immunology and allergy assays, have merged to create a new specialty diagnostics laboratory.

The merger creates a combined company with more than 200 employees that serves more than 4,000 physicians, hospitals, commercial laboratories and biopharmaceutical companies. The new company's broad test menu includes cellular, immunology, and allergy testing services as well as molecular assays that detect and monitor microbial pathogens.

Ampersand Ventures, the majority shareholder in IBT, has made an additional investment and is the majority shareholder of ViraCor-IBT. Ampersand Venture Partner Laurence R. McCarthy, PhD, who served as the Executive Chairman of IBT's board, will serve as Executive Chairman of the combined company. Herbert Hooper, PhD, and Peter Glick, both General Partners of Ampersand and previously on the board of directors at IBT, will serve on the board of ViraCor-IBT.

Established in 2000, ViraCor is a unique clinical reference and research laboratory with particular expertise in molecular infectious disease testing and in understanding the special needs of patients with compromised immune systems. These patients include those who have had organ transplants as well as cancer patients, individuals with autoimmune disorders and pre-term infants who have weaker immune systems. In addition to serving hospitals and physicians, ViraCor works with pharmaceutical companies and clinical researchers to conduct clinical trials.

IBT was founded in 1983 and is a premier allergy and immunology laboratory. It offers esoteric molecular and cellular immunology services for pharmaceutical clinical trials and patient care diagnostic testing. IBT's extensive experience and leading-edge research enable it to offer clients the most advanced immunodiagnostic services available in areas such as immune deficiency, autoimmune disease, skin allergy, drug immunogenicity and immunogenomics.

The combined company will operate out of its two current laboratory facilities located 22 miles apart in Lee's Summit, MO and Lenexa, KS. ViraCor founder and CEO Phillip "Flip" Short will step down from his role as CEO and serve on the company's board of directors. IBT founder Dr. John Halsey will continue as senior scientific advisor and director of IBT's laboratory.

For more information about ViraCor and IBT regarding the merger, visit www.ViraCorIBT.com.